Search

Search results

375 results found

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.

Thaçi, Diamant, Ron Vender, Menno A de Rie, Curdin Conrad, David M Pariser, Bruce Strober, Veerle Vanvoorden, et al. 2023. “Safety and Efficacy of Bimekizumab through 2 Years in Patients With Moderate-to-Severe Plaque Psoriasis: Longer-Term Results from the BE SURE Randomized Controlled Trial and the Open-Label Extension from the BE BRIGHT Trial.”. The British Journal of Dermatology 188 (1): 22-31.

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.

Reich, Kristian, Christopher E M Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, et al. 2020. “Maintenance of Clinical Response and Consistent Safety Profile With up to 3 years of Continuous Treatment With Guselkumab: Results from the VOYAGE 1 and VOYAGE 2 Trials.”. Journal of the American Academy of Dermatology 82 (4): 936-45.